A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Study identifier:D2912C00002

ClinicalTrials.gov identifier:NCT05794672

EudraCT identifier:2022-000426-22

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 1, Randomised, Single-blind, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Elarekibep Given Twice Daily as Inhaled or a Single IV Formulation in Healthy Japanese Subjects

Medical condition

Healthy subjects (Indication: Asthma)

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Elarekibep, Placebo

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

20 Years - 55 Years

Date

Study Start Date: 11 Apr 2023
Primary Completion Date: 08 Jul 2023
Study Completion Date: 08 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria